P2.04-14 Tumor Mutational Burden Assessed by a Targeted NGS Assay Predicts Benefit From Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1238
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

The Predictive Value of Tumor Mutation Burden for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer Is Affected by Patients’ Age

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2020English

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Current Treatment Options in Oncology
OncologyPharmacology
2019English

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Open Access Journal of Oncology and Medicine
2018English

Immune Checkpoint Modulation for Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

P2.04-13 the Immune Checkpoint, HVEM Contribute to Immune Escape in Non Small Cell Lung Cancer of Lacking PDL1 Expression

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.04-28 Use of Immune Checkpoint Inhibitors (ICIs) in Patients With Refractory Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status (PS)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Receiving Concurrent Metformin and Immune Checkpoint Inhibitors

Lung Cancer Management
2019English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy